Evidence map›Paper›PMID 42093227›Full record

ArticleEnvironmental science & technology2026

Environmentally Safe and Just Pharmacy: A Framework and Action Plan for Operating within the Earth System Boundary for Novel Entities.

Alistair B A Boxall, Priyanie Amerasinghe, Sally Beckenham, Michael G Bertram, Sally Gaw, Austin D Gray, Karen A Kidd, Laura M Langan, Kenneth M Y Leung, Jack L Manera and 3 more

Abstract read
In one paragraph

Article in Environmental science & technology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Alistair B A BoxallDepartment of Environment and Geography, University of York, York, North Yorkshire YO10 5NG, U.K.ORCID 0000-0003-3823-7516
Priyanie AmerasingheInternational Water Management Institute, Battaramulla 10120, Sri Lanka.
Sally BeckenhamDepartment of Environment and Geography, University of York, York, North Yorkshire YO10 5NG, U.K.
Michael G BertramDepartment of Wildlife, Fish, and Environmental Studies, Swedish University of Agricultural Sciences, Umeå 90183, Sweden.ORCID 0000-0001-5320-8444
Sally GawSchool of Physical and Chemical Sciences, University of Canterbury, Christchurch 8041, New Zealand.
Austin D GrayDepartment of Biological Sciences, Virginia Tech, Blacksburg, Virginia 24061-0406, United States.ORCID 0000-0002-6090-6328
Karen A KiddDepartment of Biology, McMaster University, Hamilton, Ontario L8S 4K1, Canada.ORCID 0000-0002-5619-1358
Laura M LanganDepartment of Environmental Health Sciences, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina 29208, United States.ORCID 0000-0002-2095-7163
Kenneth M Y LeungState Key Laboratory of Marine Environmental Health and Department of Chemistry, City University of Hong Kong, Hong Kong 999077, China.ORCID 0000-0002-2164-4281
Jack L ManeraSchool of Biological Sciences, Monash University, Melbourne 3800, Australia.ORCID 0009-0003-7947-6473
Karina S B MiglioranzaLaboratory of Ecotoxicology and Environmental Pollution, Mar del Plata University, IIMyC (CONICET), Mar del Plata 7600, Argentina.
Rik OldenkampAmsterdam Institute for Life and Environment (A-LIFE), Faculty of Science, Vrije Universiteit Amsterdam, Amsterdam 1081, The Netherlands.
Bryan W BrooksDepartment of Environmental Science, Baylor University, Waco, Texas 76798, United States.ORCID 0000-0002-6277-9852

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Active pharmaceutical ingredients (APIs) are essential for global health, yet their use and release into the environment contribute to the transgression of the Earth System Boundary for Novel Entities. This study proposes a novel framework for an Environmentally Safe and Just Pharmacy, establishing 4 overarching criteria and 12 subcriteria designed to ensure that the pharmaceutical lifecycle is environmentally safe and just from a novel entities perspective. Using the extensive expertise of our global author group, we conclude that current practices for API design and development, approval and monitoring, use and disposal are only partially or poorly aligned with our criteria. Key vulnerabilities include a lack of environmental considerations in early-stage drug design, widespread exceedances of environmental concentrations deemed safe to ecosystems, persistent selection for antimicrobial resistance in the environment, and severe data gaps in low- and middle-income countries. We further highlight environmental injustices, particularly for Indigenous and marginalized communities whose cultural identities and livelihoods are compromised by chemical contamination. To address these challenges, we present a 10-point roadmap for a transition to a sustainable future by 2050. This plan includes calls for green chemistry investments, the integration of social and cultural equity into risk assessments, and the global upgrade of treatment and management infrastructure. We emphasize that solutions to pharmaceutical impacts must be culturally sensitive and safeguard the dignity of vulnerable populations to ensure a truly just transition that operates within Earth System Boundaries.

Indexed as

Bulk DrugsEnvironmental PollutantsBulk DrugsEnvironmental PollutantsActive pharmaceutical ingredientsAntimicrobial resistanceEcological riskEnvironmental justiceGreen chemistryLow- and middle-income countriesPlanetary boundaries

Identifiers

PMID42093227
PMCPMC13192310

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.